Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Doxorubicin-paclitaxel: A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial
Cancer, Volume 97, No. 1, Year 2003
Notification
URL copied to clipboard!
Description
BACKGROUND. The potential cardiotoxicy of the doxorubicin-paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies. METHODS. In a large multicenter Phase III trial, 275 anthracycline naive metastatic breast carcinoma patients were randomized to receive either doxorubicin (60 mg/m2) followed 30 minutes later by paclitaxel (175 mg/m23-hour infusion; AT) or a standard doxorubicin-cyclophosphamide regimen (AC; 60/600 mg/m2). Both treatments were given once every 3 weeks for a maximum of six cycles. Close cardiac monitoring was implemented in the study design. RESULTS. Congestive heart failure (CHF) occurred in three patients in the AT arm and in one patient in the AC arm (P = 0.62). Decreases in left ventricular ejection fraction to below the limit of normal were documented in 33% AT and 19% AC patients and were not predictive of CHF development. CONCLUSIONS. AT is devoid of excessive cardiac risk among metastatic breast carcinoma patients, when the maximum planned cumulative dose of doxorubicin does not exceed 360 mg/m2. © 2003 American Cancer Society.
Authors & Co-Authors
Biganzoli, Laura
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Belgium, Brussels
Institut Jules Bordet
Cuter, Tanja
Slovenia, Ljubljana
Onkološki Inštitut Ljubljana
Bruning, Peter F.
Netherlands, Amsterdam
The Netherlands Cancer Institute
Coleman, RE E.
United Kingdom, Sheffield
Weston Park Cancer Centre
Duchateau, Luc
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Belgium, Ghent
Universiteit Gent
Rapoport, Bernardo L.
South Africa, Johannesburg
Medical Oncology Centre of Rosebank
Nooij, Marianne A.
Netherlands, Leiden
Universiteit Leiden
Delhaye, François
Belgium, Brussels
Institut Jules Bordet
Miles, David W.
United Kingdom, London
Guy's Hospital
Sulkes, Aarón
Israel, Tel Aviv-yafo
Tel Aviv University
Hamilton, Anne L.
Belgium, Brussels
European Organisation for Research and Treatment of Cancer
Piccart-Gebhart, Martine J.
Belgium, Brussels
Institut Jules Bordet
Statistics
Citations: 34
Authors: 12
Affiliations: 10
Identifiers
Doi:
10.1002/cncr.10914
ISSN:
0008543X
Research Areas
Cancer
Health System And Policy
Noncommunicable Diseases